Leadership in Respiratory Disease Therapy
Altair Therapeutics, Inc. is a biopharmaceutical company developing targeted therapeutics to treat human respiratory diseases
Altair's first compound AIR645 is currently in phase II clinical trials. In a recently completed phase I study in healthy volunteers and subjects with well controlled asthma, AIR645 was safe and well tolerated. This first-in-class compound possesses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and respiratory orphan indications. The characteristics of AIR645 provide for administration of AIR645 as an inhaled therapeutic delivered once weekly.
Altair is a privately owned, venture-funded company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to additional development projects
Altair is also developing a pipeline of other best-in-class molecules for respiratory targets exploiting the advantages of propriety 2nd generation antisense oligonucleotide chemistry.